Clinical Trials Directory

Trials / Completed

CompletedNCT02192723

A Randomized Double-blind Trial With 6 Antipsychotic Drugs for Schizophrenia

Effectiveness of 6 Antipsychotic Drugs in the Treatment of Acute Exacerbations of Chronic Inpatients With Schizophrenia: a Randomized Double-blind Study

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
550 (actual)
Sponsor
Beijing HuiLongGuan Hospital · Academic / Other
Sex
All
Age
25 Years – 60 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to compare the efficacy and side effects of 6 commonly used antipsychotic drugs in the treatment of schizophrenia in a Chinese population.

Detailed description

The relative effectiveness of second-generation (atypical) antipsychotic drugs as compared with that of older agents has been incompletely addressed, though newer agents are currently used far more commonly. The investigators compared a first-generation antipsychotic, perphenazine or haloperidol, with several newer drugs in a double-blind study. METHODS: A total of 550 patients with schizophrenia were recruited at 4 Chinese sites and randomly assigned to receive perphenazine (16 to 64 mg per day) or haloperidol(6 t0 20mg per day), olanzapine (5 to 20 mg per day), quetiapine (400 to 750 mg per day), aripiprazole (10 to 30 mg per day) or risperidone (2 to 6.0 mg per day) for up to 8 weeks.

Conditions

Interventions

TypeNameDescription
DRUGTypical antipsychoticHaloperidol (6\~20mg/day) and perphenazine (16\~64mg/day), twice per day, 8 weeks
DRUGRisperidone2\~6mg/day, twice per day, 8 weeks
DRUGOlanzapineOlanzapine, 400\~750mg/day, twice per day, 8 weeks
DRUGQuetiapineQuetiapine, 400~750mg/day, twice per day, 8 weeks
DEVICEAripiprazoleAripiprazole, 10~30mg/day, twice per day, 8 weeks
DRUGZiprasidoneZiprasidone 80\~160mg/day, twice per day, 8 weeks

Timeline

Start date
2012-06-01
Primary completion
2014-06-01
Completion
2014-06-01
First posted
2014-07-17
Last updated
2016-07-12

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT02192723. Inclusion in this directory is not an endorsement.